Accordingly, (1) human MBL may be used as early as mouse MBL-A after ischemia, since there is no competition for the substrate; (2) MBL may exert detrimental actions not requiring the activation of the complement cascade, such as those associated with coagulation system interactions, which are potentially important for stroke. This evidence concerns the gene MBL2 and Stroke.